Octagon Capital Advisors »

Lexeo Therapeutics shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Lexeo Therapeutics (LXEO) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Lexeo Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Lexeo Therapeutics held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lexeo Therapeutics by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $17M 1.7M 9.93

More positions owned by Octagon Capital Advisors

Abivax Sa Sponsored Ads (ABVX)
Dianthus Therapeutics (DNTH)
Cogent Biosciences (COGT)
Taysha Gene Therapies Com Shs (TSHA)
Gossamer Bio (GOSS)
Kymera Therapeutics (KYMR)
Arrivent Biopharma (AVBP)
Trevi Therapeutics (TRVI)
Ocular Therapeutix (OCUL)
Mind Medicine Mindmed Com New (MNMD)
Cg Oncology Call Option (CGON)
Alumis (ALMS)
Palisade Bio (PALI)
Cidara Therapeutics Com New (CDTX)
Bioage Labs (BIOA)

View all positions for Octagon Capital Advisors

Top funds holding Lexeo Therapeutics

Henderson Group
BlackRock
Paradigm Biocapital Advisors
Vestal Point Capital
Frazier Life Sciences Management
Balyasny Asset Management
Vanguard Group
Citadel Advisors
venBio Select Advisor
Affinity Asset Advisors
Woodline Partners
State Street Corporation
Millennium Management
Point72 Asset Management
Octagon Capital Advisors

View all funds holding Lexeo Therapeutics